Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer

By Larsen Finn Ole   Pfeiffer Per   Nielsen Dorte   Skougaard Kristin   Qvortrup Camilla   Vistisen Kirsten   Fromm Anne-Lene   Jøørgensen Trine L.   Bjerregaard Jon K.   Hoegdall Estrid   Jensen Benny V.  

Acta Oncologica, Vol. 50, Iss. 4, 2011-05 ,pp. : 574-577

Informa Healthcare

Access to resources Recommend Favorite

Predictability of antitumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer following failure of fluorouracil, irinotecan and oxaliplatin

By                                    

Molecular and Clinical Oncology, Vol. 3, Iss. 5, 2015-01 ,pp. : 1029-1034

Science Publishers

Access to resources Recommend Favorite

Impact of third-line treatment with irinotecan plus cetuximab on non-tumor standardized uptake values in patients with metastatic colorectal cancer

By        

Oncology Letters, Vol. 4, Iss. 1, 2012-01 ,pp. : 131-134

Spandidos Publications

Access to resources Recommend Favorite

Irinotecan and 5-Fluorouracil in colorectal cancer: time for a pause?

By Bulusu V.R.  

European Journal of Cancer, Vol. 34, Iss. 3, 1998-02 ,pp. : 286-289

Elsevier

Access to resources Recommend Favorite

Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival

By Kang Eun   Im Seock-Ah   Oh Do-Youn   Han Sae-Won   Kim Jin-Soo   Choi In   Kim Jin   Kim Yu   Kim Jee   Kim Tae-You   Lee Jong   Bang Yung-Jue   Lee Keun-Wook  

Gastric Cancer, Vol. 16, Iss. 4, 2013-10 ,pp. : 581-589

Springer Publishing Company

Access to resources Recommend Favorite